BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

NCT07474961 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom Macroglobulinaemia
Multiple Myeloma

Interventions

DRUG: teclistamab OR talquetamab OR elranatamab OR linvoseltamab
DRUG: BTK inhibitors (ibrutinib and zanubrutinib)

Sponsor

Anne Louise Tølbøll Sørensen